Hydroxytyrosol

Other Medications

Description

Hydroxytyrosol (HT) is a naturally occurring compound being studied in clinical trials for colorectal cancer. It is currently being investigated in combination with standard chemotherapy regimens (like FOLFIRI or FOLFOX, often with biologics like Cetuximab or Bevacizumab) for patients with advanced or metastatic colorectal cancer. The goal of these early-phase trials is to determine the safety and potential effectiveness of adding hydroxytyrosol to existing treatments. It is taken orally, as a capsule, daily. These trials are in the early phase (Phase 1), meaning they primarily focus on safety and finding the right dose.

Mechanism of Action

Hydroxytyrosol is a polyphenol found in olive oil and other plants. In the context of this trial, it is being given alongside standard chemotherapy for colorectal cancer. The specific way hydroxytyrosol might work against cancer cells, or how it interacts with chemotherapy, is still being investigated. Researchers are looking at its potential effects on tumor growth and response to chemotherapy.

Side Effects

Because hydroxytyrosol is being studied in early-phase trials (Phase 1) in combination with standard chemotherapy The specific side effects related to hydroxytyrosol itself are still being evaluated. Patients in the trial will likely experience side effects common to the chemotherapy regimens they are receiving (like FOLFIRI or FOLFOX And biologics like Cetuximab or Bevacizumab) Such as nausea Fatigue Diarrhea And changes in blood counts. The trial investigators will carefully monitor patients for any side effects related to the combination therapy.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06833866 med_phase_prefix1
Recruiting
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
United States